Hematologic Cancers

Ruxolitinib is Associated With Improved Renal Function in Patients With Primary Myelofibrosis

By

Susan Moench, PhD, PA-C

Publish Date June 17, 2019

A retrospective study sought to determine if treatment of myeloproliferative neoplasms with ruxolitinib may have nephroprotective effects.

Navigating Hematologic Cancers: Screening, Treatment, and Post-Treatment Considerations

By

Aimee Swickey, RN, BSN, BMTCN, ONN-CG

Publish Date June 14, 2019

Hematology nurse navigators provide patients with blood cancer with consistency in the midst of a storm, advocacy in chaos, direction when all seems lost, and most importantly, hope.

Subcutaneous Daratumumab Associated With Higher Patient Satisfaction, Drastically Fewer Infusion Reactions Than Intravenous Formulations

By

Susan Moench, PhD, PA-C

Publish Date June 3, 2019

The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.

Less-Frequently Dosed Pegylated Asparaginase: Found as Safe and Effective as Standard Pegaspargase in Younger Patients With ALL

By

Susan Moench, PhD, PA-C

Publish Date June 3, 2019

Postinduction, median nadir serum asparaginase activity was similar in patients receiving either drug, suggesting a need for dosing optimization.

Carfilzomib for Relapsed and Refractory Multiple Myeloma

Publish Date May 31, 2019

[Cancer Management and Research] A review of data from clinical trials on the use of carfilzomib, a second-generation PI, in the treatment of R/R multiple myeloma, as well as ongoing studies and prescribing advice.